EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and oral ulcers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Syndrome
• Oral Ulcers
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Apremilast Accord (apremilast)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Behcet Syndrome;Oral Ulcer. MAH: Accord Healthcare S.L.U.. Decision date: 20/03/2026